Patient-reported outcomes assessment in cancer trials

Taking stock, moving forward

Joseph Lipscomb, Bryce B. Reeve, Steven B. Clauser, Jeffrey S. Abrams, Deborah Watkins Bruner, Laurie B. Burke, Andrea M. Denicoff, Patricia A. Ganz, Kathleen Gondek, Lori M. Minasian, Ann M. O'Mara, Dennis A. Revicki, Edwin P. Rock, Julia H. Rowland, Maria Sgambati, Edward Trimble

Research output: Contribution to journalArticle

Abstract

To evaluate and improve the use of cancer trial end points that reflect the patient's own perspective, the National Cancer Institute organized an international conference, Patient-Reported Outcomes Assessment in Cancer Trials (PROACT), in 2006. The 13 preceding articles in this special issue of the Journal were commissioned in preparation for or in response to the PROACT conference, which was cosponsored by the American Cancer Society. Drawing from these articles and also commentary from the conference itself, this concluding report takes stock of what has been learned to date about the successes and challenges in patient-reported outcome (PRO) assessment in phase III, phase II, and symptom management trials in cancer and identifies ways to improve the scientific soundness, feasibility, and policy relevance of PROs in trials. Building on this synthesis of lessons learned, this article discusses specific administrative policies and management procedures to improve PRO data collection, analysis, and dissemination of findings; opportunities afforded by recent methodologic and technologic advances in PRO data collection and analysis to enhance the scientific soundness and cost efficiency of PRO use in trials; and the importance of better understanding the usefulness of PRO data to the full spectrum of cancer decision makers, including patients and families, health providers, public and private payers, regulatory agencies, and standards-setting organizations.

Original languageEnglish (US)
Pages (from-to)5133-5140
Number of pages8
JournalJournal of Clinical Oncology
Volume25
Issue number32
DOIs
StatePublished - Nov 10 2007
Externally publishedYes

Fingerprint

Patient Outcome Assessment
Neoplasms
National Cancer Institute (U.S.)
Family Health
Patient Reported Outcome Measures
Organizations
Costs and Cost Analysis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lipscomb, J., Reeve, B. B., Clauser, S. B., Abrams, J. S., Bruner, D. W., Burke, L. B., ... Trimble, E. (2007). Patient-reported outcomes assessment in cancer trials: Taking stock, moving forward. Journal of Clinical Oncology, 25(32), 5133-5140. https://doi.org/10.1200/JCO.2007.12.4644

Patient-reported outcomes assessment in cancer trials : Taking stock, moving forward. / Lipscomb, Joseph; Reeve, Bryce B.; Clauser, Steven B.; Abrams, Jeffrey S.; Bruner, Deborah Watkins; Burke, Laurie B.; Denicoff, Andrea M.; Ganz, Patricia A.; Gondek, Kathleen; Minasian, Lori M.; O'Mara, Ann M.; Revicki, Dennis A.; Rock, Edwin P.; Rowland, Julia H.; Sgambati, Maria; Trimble, Edward.

In: Journal of Clinical Oncology, Vol. 25, No. 32, 10.11.2007, p. 5133-5140.

Research output: Contribution to journalArticle

Lipscomb, J, Reeve, BB, Clauser, SB, Abrams, JS, Bruner, DW, Burke, LB, Denicoff, AM, Ganz, PA, Gondek, K, Minasian, LM, O'Mara, AM, Revicki, DA, Rock, EP, Rowland, JH, Sgambati, M & Trimble, E 2007, 'Patient-reported outcomes assessment in cancer trials: Taking stock, moving forward', Journal of Clinical Oncology, vol. 25, no. 32, pp. 5133-5140. https://doi.org/10.1200/JCO.2007.12.4644
Lipscomb J, Reeve BB, Clauser SB, Abrams JS, Bruner DW, Burke LB et al. Patient-reported outcomes assessment in cancer trials: Taking stock, moving forward. Journal of Clinical Oncology. 2007 Nov 10;25(32):5133-5140. https://doi.org/10.1200/JCO.2007.12.4644
Lipscomb, Joseph ; Reeve, Bryce B. ; Clauser, Steven B. ; Abrams, Jeffrey S. ; Bruner, Deborah Watkins ; Burke, Laurie B. ; Denicoff, Andrea M. ; Ganz, Patricia A. ; Gondek, Kathleen ; Minasian, Lori M. ; O'Mara, Ann M. ; Revicki, Dennis A. ; Rock, Edwin P. ; Rowland, Julia H. ; Sgambati, Maria ; Trimble, Edward. / Patient-reported outcomes assessment in cancer trials : Taking stock, moving forward. In: Journal of Clinical Oncology. 2007 ; Vol. 25, No. 32. pp. 5133-5140.
@article{ff597430b6174dbd93b380aa02ba4485,
title = "Patient-reported outcomes assessment in cancer trials: Taking stock, moving forward",
abstract = "To evaluate and improve the use of cancer trial end points that reflect the patient's own perspective, the National Cancer Institute organized an international conference, Patient-Reported Outcomes Assessment in Cancer Trials (PROACT), in 2006. The 13 preceding articles in this special issue of the Journal were commissioned in preparation for or in response to the PROACT conference, which was cosponsored by the American Cancer Society. Drawing from these articles and also commentary from the conference itself, this concluding report takes stock of what has been learned to date about the successes and challenges in patient-reported outcome (PRO) assessment in phase III, phase II, and symptom management trials in cancer and identifies ways to improve the scientific soundness, feasibility, and policy relevance of PROs in trials. Building on this synthesis of lessons learned, this article discusses specific administrative policies and management procedures to improve PRO data collection, analysis, and dissemination of findings; opportunities afforded by recent methodologic and technologic advances in PRO data collection and analysis to enhance the scientific soundness and cost efficiency of PRO use in trials; and the importance of better understanding the usefulness of PRO data to the full spectrum of cancer decision makers, including patients and families, health providers, public and private payers, regulatory agencies, and standards-setting organizations.",
author = "Joseph Lipscomb and Reeve, {Bryce B.} and Clauser, {Steven B.} and Abrams, {Jeffrey S.} and Bruner, {Deborah Watkins} and Burke, {Laurie B.} and Denicoff, {Andrea M.} and Ganz, {Patricia A.} and Kathleen Gondek and Minasian, {Lori M.} and O'Mara, {Ann M.} and Revicki, {Dennis A.} and Rock, {Edwin P.} and Rowland, {Julia H.} and Maria Sgambati and Edward Trimble",
year = "2007",
month = "11",
day = "10",
doi = "10.1200/JCO.2007.12.4644",
language = "English (US)",
volume = "25",
pages = "5133--5140",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "32",

}

TY - JOUR

T1 - Patient-reported outcomes assessment in cancer trials

T2 - Taking stock, moving forward

AU - Lipscomb, Joseph

AU - Reeve, Bryce B.

AU - Clauser, Steven B.

AU - Abrams, Jeffrey S.

AU - Bruner, Deborah Watkins

AU - Burke, Laurie B.

AU - Denicoff, Andrea M.

AU - Ganz, Patricia A.

AU - Gondek, Kathleen

AU - Minasian, Lori M.

AU - O'Mara, Ann M.

AU - Revicki, Dennis A.

AU - Rock, Edwin P.

AU - Rowland, Julia H.

AU - Sgambati, Maria

AU - Trimble, Edward

PY - 2007/11/10

Y1 - 2007/11/10

N2 - To evaluate and improve the use of cancer trial end points that reflect the patient's own perspective, the National Cancer Institute organized an international conference, Patient-Reported Outcomes Assessment in Cancer Trials (PROACT), in 2006. The 13 preceding articles in this special issue of the Journal were commissioned in preparation for or in response to the PROACT conference, which was cosponsored by the American Cancer Society. Drawing from these articles and also commentary from the conference itself, this concluding report takes stock of what has been learned to date about the successes and challenges in patient-reported outcome (PRO) assessment in phase III, phase II, and symptom management trials in cancer and identifies ways to improve the scientific soundness, feasibility, and policy relevance of PROs in trials. Building on this synthesis of lessons learned, this article discusses specific administrative policies and management procedures to improve PRO data collection, analysis, and dissemination of findings; opportunities afforded by recent methodologic and technologic advances in PRO data collection and analysis to enhance the scientific soundness and cost efficiency of PRO use in trials; and the importance of better understanding the usefulness of PRO data to the full spectrum of cancer decision makers, including patients and families, health providers, public and private payers, regulatory agencies, and standards-setting organizations.

AB - To evaluate and improve the use of cancer trial end points that reflect the patient's own perspective, the National Cancer Institute organized an international conference, Patient-Reported Outcomes Assessment in Cancer Trials (PROACT), in 2006. The 13 preceding articles in this special issue of the Journal were commissioned in preparation for or in response to the PROACT conference, which was cosponsored by the American Cancer Society. Drawing from these articles and also commentary from the conference itself, this concluding report takes stock of what has been learned to date about the successes and challenges in patient-reported outcome (PRO) assessment in phase III, phase II, and symptom management trials in cancer and identifies ways to improve the scientific soundness, feasibility, and policy relevance of PROs in trials. Building on this synthesis of lessons learned, this article discusses specific administrative policies and management procedures to improve PRO data collection, analysis, and dissemination of findings; opportunities afforded by recent methodologic and technologic advances in PRO data collection and analysis to enhance the scientific soundness and cost efficiency of PRO use in trials; and the importance of better understanding the usefulness of PRO data to the full spectrum of cancer decision makers, including patients and families, health providers, public and private payers, regulatory agencies, and standards-setting organizations.

UR - http://www.scopus.com/inward/record.url?scp=36849021996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36849021996&partnerID=8YFLogxK

U2 - 10.1200/JCO.2007.12.4644

DO - 10.1200/JCO.2007.12.4644

M3 - Article

VL - 25

SP - 5133

EP - 5140

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 32

ER -